Akumentis Healthcare posts Rs 66 Cr profit in FY25, revenue grows 9%

Share via:


Akumentis Healthcare, a pharmaceutical company, reported a profit of Rs 66 crore in the fiscal year ending March 2025, marking a 16.8% increase compared to FY24. The company achieved this growth on the back of consistent revenue and controlled operating costs.

Akumentis’ revenue from operations grew by 9% to Rs 433.5 crore in FY25 from Rs 398 crore in FY24, according to its financial statement sourced from the Registrar of Companies (RoC).

Akumentis financials

Akumentis Healthcare operates on a branded formulations model, focusing on prescription-driven pharmaceuticals…



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Popular

More Like this

Akumentis Healthcare posts Rs 66 Cr profit in FY25, revenue grows 9%


Akumentis Healthcare, a pharmaceutical company, reported a profit of Rs 66 crore in the fiscal year ending March 2025, marking a 16.8% increase compared to FY24. The company achieved this growth on the back of consistent revenue and controlled operating costs.

Akumentis’ revenue from operations grew by 9% to Rs 433.5 crore in FY25 from Rs 398 crore in FY24, according to its financial statement sourced from the Registrar of Companies (RoC).

Akumentis financials

Akumentis Healthcare operates on a branded formulations model, focusing on prescription-driven pharmaceuticals…



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

More like this

Apple hits $4 trillion milestone ahead of earnings report...

Apple hit a company milestone on Tuesday as...

Sunday Night Football: How to Watch Seahawks vs. Commanders...

When to watch Seattle Seahawks vs. Washington CommandersSunday, Nov....

Popular